Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Taysha Gene Therapies, Inc. logoTaysha Gene Therapies, Inc.

TSHA · Nasdaq · USD · Market cap $1.3B · 99 employees

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central ner…

FAIL · Does not pass the screen
3.72 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price3.72 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 3.00x the price, above our 2.00x limit.
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.65)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Accumulation ?
Screened · screened 2026-11-20
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.65, read 2026-11-18
  • Ethical does not pass the values gate
Price3.72 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-19Read Accumulation3.99-6.8% to today Markup gives way to Accumulation after a 7% slide in 7 days
2026-11-12Read Markup4.28-13.1% to today Distribution gives way to Markup first Markup read since November
2026-11-08Read Distribution4.33-14.1% to today ✓Markup gives way to Distribution
2026-11-07Read Markup4.33-14.1% to today Distribution gives way to Markup after a 5% rise in 13 days

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Taysha Gene Therapies, Inc. holds its Accumulation at $3.72. The statistical read favours the sellers, held for 6 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 6 days
Price at the screen$3.72
ValuationN/A trailing · -10.32 forward price to earnings
Values screenFAIL · score 70.0
Beta1.31
The Workings

Five Screens: TSHA's Results

FAIL. Accounts receivable

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 20.43% Below 33% Pass
Interest-bearing cash 0.00% Below 33% Pass
Receivables 93.14% Below 49% Fail
Revenue purity 94.38% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Taysha Gene Therapies,'s business is fine, but its receivables are about 93% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when TSHA's ethical verdict changes

Today TSHA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 3.00x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
9.00Street low 12.00Street average 19.00Street high 3.72Price

Street: 13 covering, consensus Strong Buy. Average target +223%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-10.3x
EPS, trailing-0.42
EPS, forward-0.39
Profit margin0.0%currently unprofitable
Return on equity-54.2%not currently earning a positive return on equity
FCF yield-6.92%
Debt to equity0.15minimal debt: a conservative balance sheet
Current ratio18.56comfortably covers its short-term bills
Beta1.31moves a little more than the market
Short interest, float0.17%
52-week range3.46 - 7.30
Market cap$1.3B
Employees99

TSHA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $3.99 +0.0% Entry 25
2026-11-19 Accumulation · changed $3.99 -6.8% Entry 24

The framework has shifted from markup to accumulation since the last review.

2026-11-12 Markup · changed $4.28 +0.1% Entry 23

The framework has shifted from distribution to markup since the last review.

2026-11-11 Distribution $4.28 -2.2% Entry 22
2026-11-10 Distribution $4.37 +0.9% Entry 21
2026-11-09 Distribution $4.33 +0.0% Entry 20
2026-11-08 Distribution · changed $4.33 +0.0% Entry 19

The framework has shifted from markup to distribution since the last review.

2026-11-07 Markup · changed $4.33 +5.9% Entry 18

The framework has shifted from distribution to markup since the last review.

2026-11-06 Distribution $4.09 +0.0% Entry 17
2026-11-04 Distribution $4.09 -1.0% Entry 16

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on TSHA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in TSHA's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $6.82 -20.8% · $792 -20.8%
2 months $4.49 +20.3% · $1,203 +20.3%
3 months $4.61 +17.1% · $1,171 +17.1%
6 months $5.76 -6.3% · $938 -6.3%
1 year $2.61 +106.9% · $2,069 +106.9%
2 years $3.92 +37.8% · $1,378 +37.8%
3 years $0.86 +527.9% · $6,279 +527.9%
5 years $24.51 -78.0% · $220 -78.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever TSHA does next, these words stay.

Taysha Gene Therapies, Inc. · TSHA · Accumulation · $3.72
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.